De novo antibody design is here

Read our technical report

Designing antibodies with atomic precision

Expanding the universe of druggable targets by developing integrated AI and experimental technologies

AI is the most rapidly evolving and impactful technology humanity has possessed. We can use it to design drugs and their interactions with atomic precision.

Although this represents a step change for drug design, the full complexity of human biology surpasses our understanding and AI's training scope. So, it's critical that we also develop methods to empirically measure human-relevant drug properties at scale.

At Nabla we believe it's the close integration of AI-guided design and wet-lab driven measurement that will enable the design of drugs with superior manufacturability, safety, and efficacy for diseases that elude us today.

Platform

Generative drug design meets massively parallel experimentation

Founded by pioneers of protein language modeling, Nabla develops generative models, multiplexed screens, and protein characterization technologies and applies them to design antibodies against the most challenging disease targets, from GPCRs to ion channels.

Discover our platform

Partners

Partnering with the world's leading pharmaceutical companies

To maximize the impact of our platform, we are partnering with leading pharmaceutical companies to design drugs and bring them to patients.

Partner with us

Company

We're a focused, creative team with high scientific standards